Burke Steven Keith 4

What Happened

• Steven Keith Burke, SVP and Chief Medical Officer of Akebia Therapeutics (AKBA), was granted two equity awards on January 30, 2026: 204,000 restricted stock units (RSUs) and 320,000 derivative awards (stock options). Both grants are reported at $0.00 because they are compensatory awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-01-30; Form 4 filed 2026-02-03 (timely — within the two-business-day filing window).
• Grants: 204,000 RSUs (reported acquisition amount $0.00) and 320,000 derivative awards/options (reported acquisition amount $0.00).
• Vesting (per footnotes): RSUs vest one-third on each of the first, second and third anniversaries of the grant date, subject to continued service. Options vest over four years: 25% at the first anniversary, then the remainder in equal quarterly installments thereafter, subject to continued service.
• Holdings note: footnotes also reference 3,000 shares bought under the company’s ESPP in 2025 (1,500 on June 30, 2025 and 1,500 on Dec 31, 2025). The filing does not state the total shares owned by Burke after these grants.
• Nature of transaction: Award/Grant (code A) — no cash paid now; these are compensation awards, not immediate purchases or sales.

Context

• These are standard compensation awards under Akebia’s 2023 Stock Incentive Plan meant to align executive pay with long-term performance. The derivative award is an option grant (not an exercise); no shares were sold or exercised at grant. Such grants are common and do not by themselves indicate current buying or selling sentiment.